An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based TherapeuticsJennifer D. Sisler, Tod A. Harper, Helen L. Lightfoot et al.|International Journal of Toxicology|2026Cited by 1